Regeneron Pharmaceuticals (NASDAQ:REGN) Director Arthur Ryan Sells 200 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Up 4.1%

Shares of REGN stock opened at $676.23 on Wednesday. The stock has a market cap of $71.49 billion, a P/E ratio of 16.48, a PEG ratio of 1.43 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 52 week low of $537.45 and a 52 week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $648.64 and its two-hundred day simple moving average is $724.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the business posted $8.22 earnings per share. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.46 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. WPG Advisers LLC lifted its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $29,000. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on REGN shares. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Finally, HSBC lowered their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $790.46.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron to buy from hold, signaling improved confidence in the stock’s outlook. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Truist kept a buy rating and reiterated a new price target of $769, suggesting meaningful upside from current levels despite a slight target cut. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation
• Positive Sentiment: HSBC also maintained a buy rating after trimming its target to $880, reinforcing the view that analysts still see room for gains. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock and noted its favorable earnings surprise history, which may be building investor confidence ahead of the next report. Here's Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada lowered its target to $696 and kept a sector perform rating, which is a more cautious signal but still implies modest upside. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Jim Cramer’s comments that biotech could become “the hottest group in the market” added sector-wide optimism, but this was a broad industry call rather than Regeneron-specific news. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged 10b5-1 transaction, which can sometimes weigh on sentiment even though the sale was relatively small. SEC filing for director sale
• Negative Sentiment: Cantor Fitzgerald and RBC both trimmed their price targets this week, suggesting analysts have slightly more tempered expectations for near-term upside. Regeneron price target changes

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.